Genovis AB (publ.) - Asset Resilience Ratio
Genovis AB (publ.) (GENO) has an Asset Resilience Ratio of 43.18% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Genovis AB (publ.) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Genovis AB (publ.)'s Asset Resilience Ratio has changed over time. See Genovis AB (publ.) (GENO) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Genovis AB (publ.)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Genovis AB (publ.) (GENO) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr163.19 Million | 43.18% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr163.19 Million | 43.18% |
Asset Resilience Insights
- Very High Liquidity: Genovis AB (publ.) maintains exceptional liquid asset reserves at 43.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Genovis AB (publ.) Industry Peers by Asset Resilience Ratio
Compare Genovis AB (publ.)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Genovis AB (publ.) (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Genovis AB (publ.).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.18% | Skr163.19 Million ≈ $17.56 Million |
Skr377.93 Million ≈ $40.67 Million |
-8.57pp |
| 2024-12-31 | 51.75% | Skr169.44 Million ≈ $18.23 Million |
Skr327.41 Million ≈ $35.23 Million |
+9.08pp |
| 2023-12-31 | 42.67% | Skr123.26 Million ≈ $13.26 Million |
Skr288.86 Million ≈ $31.09 Million |
-5.71pp |
| 2022-12-31 | 48.39% | Skr72.83 Million ≈ $7.84 Million |
Skr150.52 Million ≈ $16.20 Million |
-8.98pp |
| 2021-12-31 | 57.37% | Skr81.31 Million ≈ $8.75 Million |
Skr141.75 Million ≈ $15.25 Million |
+16.00pp |
| 2020-12-31 | 41.37% | Skr44.12 Million ≈ $4.75 Million |
Skr106.65 Million ≈ $11.48 Million |
+10.80pp |
| 2019-12-31 | 30.57% | Skr14.99 Million ≈ $1.61 Million |
Skr49.04 Million ≈ $5.28 Million |
+5.24pp |
| 2018-12-31 | 25.33% | Skr9.58 Million ≈ $1.03 Million |
Skr37.83 Million ≈ $4.07 Million |
+6.63pp |
| 2017-12-31 | 18.69% | Skr4.92 Million ≈ $529.22K |
Skr26.31 Million ≈ $2.83 Million |
-0.90pp |
| 2016-12-31 | 19.59% | Skr4.28 Million ≈ $460.74K |
Skr21.85 Million ≈ $2.35 Million |
-5.97pp |
| 2014-12-31 | 25.56% | Skr5.00 Million ≈ $538.08K |
Skr19.56 Million ≈ $2.11 Million |
+18.32pp |
| 2013-12-31 | 7.24% | Skr3.00 Million ≈ $322.85K |
Skr41.45 Million ≈ $4.46 Million |
-- |
About Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an… Read more